Although development of immune checkpoint inhibition strategies (ICI) targeting tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment has revolutionized cancer treatment, patients with HR+/HER2- BC have derived limited benefit. This evidence concerns the gene HR and breast cancer.